Infectious Diseases In-Vitro Diagnostics Market by Product, Technology, Indication, End-user

Description

List of Tables

The Infectious Diseases In-Vitro Diagnostics Market was valued at USD 49.06 billion in 2023, expected to reach USD 52.51 billion in 2024, and is projected to grow at a CAGR of 7.22%, to USD 79.95 billion by 2030.

The scope of the infectious diseases in-vitro diagnostics (IVD) market encompasses diagnostic tests performed on samples such as blood, tissue, and other body fluids to detect infectious diseases within the human body. This market has become essential due to rising global infectious disease prevalence, increasing demand for rapid diagnostic solutions, and the ongoing threat of pandemics like COVID-19. These diagnostics are imperative for timely and accurate diagnosis, facilitating proper treatment plans and management, thus saving lives and curbing disease spread. Key applications involve testing for diseases such as HIV, influenza, tuberculosis, hepatitis, and emerging infections, with end-use sectors including hospitals, clinical laboratories, and point-of-care settings. Market growth is significantly influenced by technological advancements like next-generation sequencing, PCR, and immunoassays leading to improved accuracy and speed. The novel use of AI and machine learning for interpreting diagnostic results also presents noteworthy opportunities. Furthermore, the growing emphasis on home testing, fueled by convenience, immediate result interpretation, and privacy, is carving a significant niche within this industry. However, challenges such as high costs of advanced diagnostics, regulatory hurdles, and limited healthcare infrastructure in developing regions restrain market expansion. Also, unreliable results due to technical limitations in specific tests can be a deterrent. A key area for innovation lies in the development of affordable, simple, yet highly sensitive portable diagnostics. These innovations can dramatically enhance accessibility, particularly in low-resource settings worldwide. Also, exploring biomarkers for novel diseases and expanding multiplex testing, which simultaneously targets multiple pathogens, can be game-changers. The nature of this market is highly dynamic, driven by the frequent emergence of new infectious threats, thus requiring continuous R&D investment and collaboration between technology providers and healthcare professionals to stay adept and responsive. Recommendations for capitalizing on market opportunities include strategic partnerships and robust investments in R&D to cultivate more effective, less expensive diagnostics.

KEY MARKET STATISTICS
Base Year [2023]	USD 49.06 billion
Estimated Year [2024]	USD 52.51 billion
Forecast Year [2030]	USD 79.95 billion
CAGR (%)	7.22%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Infectious Diseases In-Vitro Diagnostics Market

The Infectious Diseases In-Vitro Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

Market Drivers
- Increasing Prevalence and Periodic Outbreak of Infectious Diseases
- Rising Adoption of Rapid Test Kits for Diagnosis of Infectious Diseases
- Implementation of Government Initiatives to Curb Viral Diseases
Market Restraints
- Product Recalls of Infectious Disease In-vitro Diagnostics
Market Opportunities
- Advancements in Genomics and Proteomics
- Increasing Investments in R&D to Launch New IVD Products
Market Challenges
- Limited Accessibility of Infectious Diseases In-vitro Diagnostics Kits

Porter's Five Forces: A Strategic Tool for Navigating the Infectious Diseases In-Vitro Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Infectious Diseases In-Vitro Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Infectious Diseases In-Vitro Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Infectious Diseases In-Vitro Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Infectious Diseases In-Vitro Diagnostics Market

A detailed market share analysis in the Infectious Diseases In-Vitro Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Infectious Diseases In-Vitro Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Infectious Diseases In-Vitro Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Infectious Diseases In-Vitro Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Trinity Biotech PLC, Qiagen N.V., DiaSorin S.p.A, Koninklijke Philips N.V., Vela Diagnostics, InBios International, Inc., PerkinElmer, Inc., Quest Diagnostics, F. Hoffmann La-Roche Ltd., bioMerieux SA, Laboratory Corporation Of America Holdings, Sysmex Corporation, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc., Grifols, S.A., Hologic, Inc., Siemens Healthineers AG, Danaher Corporation, Quidel Corporation, Epitope Diagnostics, Inc., Genspeed Biotech GmbH, Meril Life Sciences Pvt. Ltd., Abbott Laboratories, Uniogen Oy, DX Lab Inc., Illumina, Inc., OraSure Technologies, Inc., Merck KGaA, and Becton, Dickinson and Company.

Market Segmentation & Coverage

This research report categorizes the Infectious Diseases In-Vitro Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

Based on Product, market is studied across Instruments, Reagents, and Software.
Based on Technology, market is studied across Immunochemistry, Microbiology, and Molecular Diagnostics.
Based on Indication, market is studied across Candidiasis, Chlamydia, Clostridium difficile, CRE, Gastroenteritis, Gonorrhea, Hepatitis, HIV, HPV, MRSA, Respiratory Virus, Streptococcus, TB and Drug-resistant TB, and VRE.
Based on End-user, market is studied across Academic Research Institutes, Diagnostic Laboratories, and Hospitals & Clinics.
Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Product Code: MRR-A339DAEFAD44

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Increasing Prevalence and Periodic Outbreak of Infectious Diseases
  - 5.1.1.2. Rising Adoption of Rapid Test Kits for Diagnosis of Infectious Diseases
  - 5.1.1.3. Implementation of Government Initiatives to Curb Viral Diseases
- 5.1.2. Restraints
  - 5.1.2.1. Product Recalls of Infectious Disease In-vitro Diagnostics
- 5.1.3. Opportunities
  - 5.1.3.1. Advancements in Genomics and Proteomics
  - 5.1.3.2. Increasing Investments in R&D to Launch New IVD Products
- 5.1.4. Challenges
  - 5.1.4.1. Limited Accessibility of Infectious Diseases In-vitro Diagnostics Kits
5.2. Market Segmentation Analysis
- 5.2.1. Product: Rising demand for advanced reagents for testing infectious pathogens
- 5.2.2. Technology: Expanding adoption of molecular diagnostics technology to quickly detect and quantify viral load, such as in HIV or hepatitis infections
5.3. Porter's Five Forces Analysis
- 5.3.1. Threat of New Entrants
- 5.3.2. Threat of Substitutes
- 5.3.3. Bargaining Power of Customers
- 5.3.4. Bargaining Power of Suppliers
- 5.3.5. Industry Rivalry
5.4. PESTLE Analysis
- 5.4.1. Political
- 5.4.2. Economic
- 5.4.3. Social
- 5.4.4. Technological
- 5.4.5. Legal
- 5.4.6. Environmental
5.5. Client Customization

6. Infectious Diseases In-Vitro Diagnostics Market, by Product

6.1. Introduction
6.2. Instruments
6.3. Reagents
6.4. Software

7. Infectious Diseases In-Vitro Diagnostics Market, by Technology

7.1. Introduction
7.2. Immunochemistry
7.3. Microbiology
7.4. Molecular Diagnostics

8. Infectious Diseases In-Vitro Diagnostics Market, by Indication

8.1. Introduction
8.2. Candidiasis
8.3. Chlamydia
8.4. Clostridium difficile
8.5. CRE
8.6. Gastroenteritis
8.7. Gonorrhea
8.8. Hepatitis
8.9. HIV
8.10. HPV
8.11. MRSA
8.12. Respiratory Virus
8.13. Streptococcus
8.14. TB and Drug-resistant TB
8.15. VRE

9. Infectious Diseases In-Vitro Diagnostics Market, by End-user

9.1. Introduction
9.2. Academic Research Institutes
9.3. Diagnostic Laboratories
9.4. Hospitals & Clinics

10. Americas Infectious Diseases In-Vitro Diagnostics Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Infectious Diseases In-Vitro Diagnostics Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Infectious Diseases In-Vitro Diagnostics Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
- 13.3.1. Roche Launches Next-Generation Qpcr System to Advance Clinical Needs In Molecular Diagnostics and Address Public Health Challenges
- 13.3.2. Biocare Medical Announces the Launch of ARC: The New IVD Antigen Retrieval Chamber for Reliable, Precise and Consistent Heat Induced Epitope Retrieval (HIER)
- 13.3.3. Launch of Optimer-Fc as a New Reagent Solution for Immunohistochemistry
- 13.3.4. DxLab Delivers Lab-Quality Detection of Infectious Diseases and Harmful Pathogens in a Toaster-Size Box

Companies Mentioned

1. Trinity Biotech PLC
2. Qiagen N.V.
3. DiaSorin S.p.A
4. Koninklijke Philips N.V.
5. Vela Diagnostics
6. InBios International, Inc.
7. PerkinElmer, Inc.
8. Quest Diagnostics
9. F. Hoffmann La-Roche Ltd.
10. bioMerieux SA
11. Laboratory Corporation Of America Holdings
12. Sysmex Corporation
13. Bio-Rad Laboratories, Inc.
14. Thermo Fisher Scientific Inc.
15. Grifols, S.A.
16. Hologic, Inc.
17. Siemens Healthineers AG
18. Danaher Corporation
19. Quidel Corporation
20. Epitope Diagnostics, Inc.
21. Genspeed Biotech GmbH
22. Meril Life Sciences Pvt. Ltd.
23. Abbott Laboratories
24. Uniogen Oy
25. DX Lab Inc.
26. Illumina, Inc.
27. OraSure Technologies, Inc.
28. Merck KGaA
29. Becton, Dickinson and Company